Celastrol alleviates airway hyperresponsiveness and inflammation in obese asthma through mediation of alveolar macrophage polarization
Copyright © 2024 Elsevier B.V. All rights reserved..
Obese asthma is a unique asthma phenotype that decreases sensitivity to inhaled corticosteroids, and currently lacks efficient therapeutic medication. Celastrol, a powerful bioactive substance obtained naturally from the roots of Tripterygium wilfordii, has been reported to possess the potential effect of weight loss in obese individuals. However, its role in the treatment of obese asthma is not fully elucidated. In the present study, diet-induced obesity (DIO) mice were used with or without ovalbumin (OVA) sensitization, the therapeutic effects of celastrol on airway hyperresponsiveness (AHR) and airway inflammation were examined. We found celastrol significantly decreased methacholine-induced AHR in obese asthma, as well as reducing the infiltration of inflammatory cells and goblet cell hyperplasia in the airways. This effect was likely due to the inhibition of M1-type alveolar macrophages (AMs) polarization and the promotion of M2-type macrophage polarization. In vitro, celastrol yielded equivalent outcomes in Lipopolysaccharide (LPS)-treated RAW264.7 macrophage cells, featuring a reduction in the expression of M1 macrophage makers (iNOS, IL-1β, TNF-α) and heightened M2 macrophage makers (Arg-1, IL-10). Mechanistically, the PI3K/AKT signaling pathway has been implicated in these processes. In conclusion, we demonstrated that celastrol assisted in mitigating various parameters of obese asthma by regulating the balance of M1/M2 AMs polarization.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:972 |
---|---|
Enthalten in: |
European journal of pharmacology - 972(2024) vom: 05. Apr., Seite 176560 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Liang, Yafeng [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 26.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ejphar.2024.176560 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370938607 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370938607 | ||
003 | DE-627 | ||
005 | 20240427232251.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240412s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejphar.2024.176560 |2 doi | |
028 | 5 | 2 | |a pubmed24n1390.xml |
035 | |a (DE-627)NLM370938607 | ||
035 | |a (NLM)38604543 | ||
035 | |a (PII)S0014-2999(24)00248-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Liang, Yafeng |e verfasserin |4 aut | |
245 | 1 | 0 | |a Celastrol alleviates airway hyperresponsiveness and inflammation in obese asthma through mediation of alveolar macrophage polarization |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.04.2024 | ||
500 | |a Date Revised 26.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a Obese asthma is a unique asthma phenotype that decreases sensitivity to inhaled corticosteroids, and currently lacks efficient therapeutic medication. Celastrol, a powerful bioactive substance obtained naturally from the roots of Tripterygium wilfordii, has been reported to possess the potential effect of weight loss in obese individuals. However, its role in the treatment of obese asthma is not fully elucidated. In the present study, diet-induced obesity (DIO) mice were used with or without ovalbumin (OVA) sensitization, the therapeutic effects of celastrol on airway hyperresponsiveness (AHR) and airway inflammation were examined. We found celastrol significantly decreased methacholine-induced AHR in obese asthma, as well as reducing the infiltration of inflammatory cells and goblet cell hyperplasia in the airways. This effect was likely due to the inhibition of M1-type alveolar macrophages (AMs) polarization and the promotion of M2-type macrophage polarization. In vitro, celastrol yielded equivalent outcomes in Lipopolysaccharide (LPS)-treated RAW264.7 macrophage cells, featuring a reduction in the expression of M1 macrophage makers (iNOS, IL-1β, TNF-α) and heightened M2 macrophage makers (Arg-1, IL-10). Mechanistically, the PI3K/AKT signaling pathway has been implicated in these processes. In conclusion, we demonstrated that celastrol assisted in mitigating various parameters of obese asthma by regulating the balance of M1/M2 AMs polarization | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Alveolar macrophages | |
650 | 4 | |a Asthma | |
650 | 4 | |a Celastrol | |
650 | 4 | |a Obesity | |
650 | 4 | |a PI3K/AKT | |
650 | 7 | |a celastrol |2 NLM | |
650 | 7 | |a L8GG98663L |2 NLM | |
650 | 7 | |a Pentacyclic Triterpenes |2 NLM | |
650 | 7 | |a Triterpenes |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
650 | 7 | |a Phosphatidylinositol 3-Kinases |2 NLM | |
650 | 7 | |a EC 2.7.1.- |2 NLM | |
650 | 7 | |a Ovalbumin |2 NLM | |
650 | 7 | |a 9006-59-1 |2 NLM | |
700 | 1 | |a Shen, Sijia |e verfasserin |4 aut | |
700 | 1 | |a Ye, Xiaoxiao |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Weixi |e verfasserin |4 aut | |
700 | 1 | |a Lin, Xixi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 972(2024) vom: 05. Apr., Seite 176560 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
773 | 1 | 8 | |g volume:972 |g year:2024 |g day:05 |g month:04 |g pages:176560 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2024.176560 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 972 |j 2024 |b 05 |c 04 |h 176560 |